Decision-Making Process Surrounding Biosimilar Implementation

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asked Gottlieb how she navigates choosing between a biosimilar or reference product for patients.

Gottlieb said most dermatologists prefer the reference adalimumab (Humira) given familiarity, as they lack education on biosimilar approval and interchangeability. She strongly prefers a biosimilar with interchangeability data and wants to know when patients switch. She would appeal for an interchangeable biosimilar over one without data. She also prefers a biosimilar studied in the disease being treated due to different outcomes and doses.

Strand disagreed, noting rheumatology patients frequently switch medications. Adalimumab is usually the first biologic, but then providers tend to switch to another agent after failure. Biosimilars will likely be first-line treatment, with little provider choice. Though interchangeability data is preferable, current biosimilars are highly similar without it. Providers rarely switch within a class, which limits adalimumab biosimilar opportunities. Prior authorizations are frustrating and may limit choices among the many adalimumab biosimilars.

Haumschild agreed providers should help select preferred therapies and interchangeable options. Provider comfort varies, but experience over time increases acceptance, as with bevacizumab.

Video synopsis is AI-generated and reviewed by editorial staff.